National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Access to Care (10)
- Adverse Drug Events (ADE) (2)
- Alcohol Use (4)
- Antibiotics (1)
- Behavioral Health (22)
- Breast Feeding (1)
- Cancer (8)
- Cancer: Cervical Cancer (1)
- Cardiovascular Conditions (5)
- Care Coordination (1)
- Caregiving (1)
- Care Management (5)
- Children/Adolescents (12)
- Chronic Conditions (26)
- Clinical Decision Support (CDS) (2)
- Clinician-Patient Communication (6)
- Colonoscopy (1)
- Communication (4)
- Community-Based Practice (2)
- Comparative Effectiveness (5)
- COVID-19 (3)
- Cultural Competence (1)
- Data (1)
- Depression (16)
- Diabetes (3)
- Diagnostic Safety and Quality (12)
- Disparities (10)
- Domestic Violence (1)
- Education: Academic (2)
- Education: Continuing Medical Education (3)
- Education: Patient and Caregiver (5)
- Elderly (6)
- Electronic Health Records (EHRs) (4)
- Emergency Department (3)
- Emergency Medical Services (EMS) (3)
- Evidence-Based Practice (15)
- Family Health and History (1)
- Guidelines (6)
- Healthcare Cost and Utilization Project (HCUP) (4)
- Healthcare Costs (17)
- Healthcare Delivery (6)
- Healthcare Utilization (5)
- Health Information Exchange (HIE) (1)
- Health Information Technology (HIT) (14)
- Health Insurance (5)
- Health Literacy (2)
- Health Promotion (7)
- Health Services Research (HSR) (2)
- Health Status (4)
- Heart Disease and Health (6)
- Hepatitis (8)
- Hospitalization (10)
- Hospital Readmissions (3)
- Hospitals (1)
- (-) Human Immunodeficiency Virus (HIV) (256)
- Implementation (2)
- Infectious Diseases (21)
- Injuries and Wounds (1)
- Inpatient Care (1)
- Kidney Disease and Health (4)
- Lifestyle Changes (5)
- Long-Term Care (4)
- Low-Income (6)
- Medicaid (11)
- Medical Expenditure Panel Survey (MEPS) (1)
- Medicare (5)
- Medication (54)
- Men's Health (8)
- Mortality (4)
- Nursing (1)
- Nursing Homes (4)
- Nutrition (5)
- Obesity (3)
- Obesity: Weight Management (3)
- Opioids (8)
- Outcomes (14)
- Pain (7)
- Palliative Care (1)
- Patient-Centered Healthcare (4)
- Patient-Centered Outcomes Research (13)
- Patient Adherence/Compliance (34)
- Patient and Family Engagement (5)
- Patient Experience (2)
- Patient Safety (2)
- Patient Self-Management (9)
- Policy (5)
- Practice Patterns (1)
- Pregnancy (5)
- Prevention (45)
- Primary Care (4)
- Primary Care: Models of Care (1)
- Provider (3)
- Public Health (5)
- Quality Measures (2)
- Quality of Care (3)
- Quality of Life (6)
- Racial and Ethnic Minorities (40)
- Research Methodologies (2)
- Respiratory Conditions (2)
- Risk (25)
- Rural Health (1)
- Screening (26)
- Sex Factors (3)
- Sexual Health (20)
- Shared Decision Making (2)
- Simulation (3)
- Sleep Problems (2)
- Social Determinants of Health (9)
- Social Stigma (25)
- Stroke (2)
- Substance Abuse (17)
- Surgery (1)
- Teams (1)
- Telehealth (7)
- Tobacco Use (6)
- Tobacco Use: Smoking Cessation (1)
- Training (3)
- Transitions of Care (2)
- Treatments (2)
- U.S. Preventive Services Task Force (USPSTF) (6)
- Uninsured (2)
- Urban Health (8)
- Vaccination (5)
- Vulnerable Populations (14)
- Women (27)
- Young Adults (7)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 25 of 256 Research Studies DisplayedOlaya F, Brin M, Caraballo PB
A randomized controlled trial of the dissemination of an mHealth intervention for improving health outcomes: the WiseApp for Spanish-speakers living with HIV study protocol.
The purpose of this study is to test the effectiveness of an mHealth tool to improve adherence to HIV medication in Spanish-speaking people living in New York City and the Dominican Republic. The researchers developed the WiseApp study as a two-arm randomized controlled trial. The 248 participants from New York and the Dominican Republic were randomly assigned to receive a CleverCap pill bottle that is linked to the WiseApp (intervention) or to the standard of care (control). The participants completed surveys at the baseline, 3-month, 6-month, and 12-month follow-up visits. Through blood draws at each study timepoint, the study team collected HIV-1 viral load and CD4 count results. Results will be forthcoming.
AHRQ-funded; HS028523.
Citation: Olaya F, Brin M, Caraballo PB .
A randomized controlled trial of the dissemination of an mHealth intervention for improving health outcomes: the WiseApp for Spanish-speakers living with HIV study protocol.
BMC Public Health 2024 Jan 17; 24(1):201. doi: 10.1186/s12889-023-17538-y..
Keywords: Human Immunodeficiency Virus (HIV), Telehealth, Health Information Technology (HIT), Cultural Competence, Outcomes
Cuca YP, Horvat C, Corless IB IB
The social, mental, and physical health impacts of the COVID-19 pandemic on people with HIV: protocol of an observational international multisite study.
The authors described the protocol for an international multisite observational study based on the SPIRIT guidelines to examine impact on the health and HIV outcomes for immunocompromised individuals such as people with HIV (PWH) from COVID-19 and from the strategies enacted to contain it. Investigators will recruit PWH to complete the study online or in-person. Study questions will address demographics, HIV continuum of care indicators, mental and social health, COVID-19 and vaccination knowledge, attitudes, behaviors, and fears; and overall outcomes. Results of this study can inform responses to future public health crises to minimize impacts on vulnerable populations such as PWH.
AHRQ-funded; HS028523.
Citation: Cuca YP, Horvat C, Corless IB IB .
The social, mental, and physical health impacts of the COVID-19 pandemic on people with HIV: protocol of an observational international multisite study.
J Assoc Nurses AIDS Care 2024 Jan-Feb; 35(1):60-74. doi: 10.1097/jnc.0000000000000444..
Keywords: COVID-19, Human Immunodeficiency Virus (HIV), Chronic Conditions
Wurcel AG, Guardado R, Grussing ED
Racial differences in testing for infectious diseases: an analysis of jail intake data.
This analysis examines HIV and hepatitis C virus (HCV) testing in Middlesex House of Corrections (MHOC) in Massachusetts. Only 38% of incarcerated individuals who requested testing received it. Black non-Hispanic and Hispanic individuals were more likely to request and complete testing compared to white individuals. These disparities may reflect broader issues of access to care. The study highlights the need for improved testing completion rates and interdisciplinary collaboration in jails.
AHRQ-funded; HS026008.
Citation: Wurcel AG, Guardado R, Grussing ED .
Racial differences in testing for infectious diseases: an analysis of jail intake data.
PLoS One 2023 Dec 20; 18(12):e0288254. doi: 10.1371/journal.pone.0288254.
Keywords: Hepatitis, Human Immunodeficiency Virus (HIV), Racial and Ethnic Minorities, Vulnerable Populations
Wiehe SE, Nelson TL, Aalsma MC
HIV care continuum among people living with HIV and history of arrest and mental health diagnosis.
The purpose of this retrospective cohort study was to explore relationships between the overlap of justice involvement and psychiatric comorbidities with HIV outcomes among people living with HIV (PLWH). The researchers included 5,730 PLWH 13 years of age and older living in Marion County Indiana in 2018. The study found that linkage to care (LTC) decreased among those with an arrest vs those without an arrest. Mental health diagnoses had no significant impact on LTC. The researchers controlled for demographics and substance use disorder and the resulting analyses indicated a protective effect of arrest history on the likelihood of retention in care (RIC) and undetectable viral load (UVL). Having a diagnosis of a mental health issue also increased the likelihood of RIC and UVL. The study results were mediated by outpatient care use, but an arrest or the diagnosis of a mental health issue increased the likelihood of RIC among PLWH and a history of low use of outpatient services.
AHRQ-funded; HS023318; HS024296.
Citation: Wiehe SE, Nelson TL, Aalsma MC .
HIV care continuum among people living with HIV and history of arrest and mental health diagnosis.
J Acquir Immune Defic Syndr 2023 Dec 15; 94(5):403-11. doi: 10.1097/qai.0000000000003296..
Keywords: Human Immunodeficiency Virus (HIV)
Tracer H, Lorei NC
AHRQ Author: Tracer H
Preexposure prophylaxis to prevent acquisition of HIV.
This case study described a 28-year-old woman presented to a community health clinic for sexually transmitted infection (STI) testing. Case study questions related to the USPSTF recommendation on Preexposure Prophylaxis (PrEP) to prevent acquisition of HIV, guidelines for candidacy for PrEP, guidelines for the use of PrEP for the primary prevention of HIV in adults.
AHRQ-authored.
Citation: Tracer H, Lorei NC .
Preexposure prophylaxis to prevent acquisition of HIV.
Am Fam Physician 2023 Dec; 108(6):617-18..
Keywords: U.S. Preventive Services Task Force (USPSTF), Human Immunodeficiency Virus (HIV), Prevention, Evidence-Based Practice
Ruderman SA, Odden MC, Webel AR
Tobacco smoking and pack-years are associated with frailty among people with HIV.
This study examines the association of frailty with tobacco smoking and pack-years among people with HIV (PWH). The authors identified 8,608 PWH across 6 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites who completed ≥2 patient-reported outcome assessments, including a frailty phenotype measuring unintentional weight loss, poor mobility, fatigue, and inactivity, scored 0-4. The authors measured smoking as baseline pack-years and time-updated never, former, or current use with cigarettes/day. They used Cox models to associate smoking with risk of incident frailty (score ≥3) and deterioration (frailty score increase by ≥2 points), adjusted for demographics, antiretroviral medication, and time-updated CD4 count. Mean follow-up period of PWH was 5.3 years, the mean age at baseline was 45 years, 15% were female, and 52% were non-White. At baseline, 60% reported current or former smoking and both were associated with higher incident frailty risk, as was higher pack-years. Current smoking (among younger PWH) and pack-years were associated with higher risk of deterioration, but not former smoking.
AHRQ-funded; HS026154.
Citation: Ruderman SA, Odden MC, Webel AR .
Tobacco smoking and pack-years are associated with frailty among people with HIV.
J Acquir Immune Defic Syndr 2023 Oct 1; 94(2):135-42. doi: 10.1097/qai.0000000000003242..
Keywords: Tobacco Use, Human Immunodeficiency Virus (HIV), Chronic Conditions, Health Status
Chou R, Spencer H, Bougatsos C
Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US Preventive Services Task Force.
This article updates research used in the 2019 US Preventive Services Task Force final recommendation on use of oral preexposure prophylaxis (PrEP) to prevent HIV in adults at increased risk. The summary includes newer PrEP regimens that were not available for the 2019 final recommendation. A literature review was conducted that included randomized clinical trials of PrEP vs placebo or no PrEP or newer vs older PrEP regimens and diagnostic accuracy studies of instruments for predicting incident HIV infection. Thirty-two studies were included in the review (20 randomized clinical trials [n = 36,543] and 12 studies of diagnostic accuracy [n = 5,544,500]). Eleven trials in the 2019 review found oral PrEP associated with decreased HIV infection risk vs placebo or no PrEP. One new trial (n = 5335) found oral tenofovir alafenamide/emtricitabine (TAF/FTC) to be noninferior to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in men who have sex with men. Two new trials found long-acting injectable cabotegravir associated with decreased risk of HIV infection vs oral TDF/FTC in cisgender men who have sex with men and transgender women [n = 4490] and RR, 0.11 in cisgender women [n = 3178]). Discrimination of instruments for predicting incident HIV infection was found to be moderate in men who have sex with men (5 studies; n = 25,488) and moderate to high in general populations of persons without HIV (2 studies; n = 5,477,291).
AHRQ-funded; 75Q80120D00006.
Citation: Chou R, Spencer H, Bougatsos C .
Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2023 Aug 22; 330(8):746-63. doi: 10.1001/jama.2023.9865..
Keywords: U.S. Preventive Services Task Force (USPSTF), Human Immunodeficiency Virus (HIV), Prevention, Medication, Evidence-Based Practice
Teixeira da Silva D, Makeneni S, Wall H
Measuring quality STI care among adolescent female primary care patients in Philadelphia.
The purpose of this study was to develop and apply a cross-setting, sexually transmitted infection (STI) Care Continuum to improve STI care quality, to assess adherence to guideline-recommended care, and to standardize progress measurement toward National Strategic goals. Review of the CDC STI treatment guidelines identified seven distinct steps of care for gonorrhea, chlamydia, and syphilis; researchers used Youth Risk Behavior Surveillance Survey data to estimate step 1, and electronic health record data for steps 2, 3, 4, 6 and 7. The researchers concluded that local application of an STI Care Continuum identified STI testing, retesting, and HIV testing as areas for improvement. Similar methods may be applied to target resources, standardize data collection and reporting, and improve STI care quality.
AHRQ-funded; HS026116.
Citation: Teixeira da Silva D, Makeneni S, Wall H .
Measuring quality STI care among adolescent female primary care patients in Philadelphia.
Sex Transm Infect 2023 Jun; 99(4):272-75. doi: 10.1136/sextrans-2022-055623..
Keywords: Children/Adolescents, Sexual Health, Infectious Diseases, Primary Care, Women, Human Immunodeficiency Virus (HIV), Quality Measures, Quality of Care
Ruderman SA, Nance RM, Drumright LN
Development of Frail RISC-HIV: a risk score for predicting frailty risk in the short-term for care of people with HIV.
The authors developed RISC-HIV, a frailty prediction risk score for HIV clinical decision-making. They predicted frailty risk among people with HIV (PWH) at seven US HIV clinics and followed for up to 2 years to identify short-term predictors of becoming frail. They concluded that RISC-HIV is a simple, easily implemented tool to assist in classifying PWH at risk for frailty in clinics.
AHRQ-funded; HS026154.
Citation: Ruderman SA, Nance RM, Drumright LN .
Development of Frail RISC-HIV: a risk score for predicting frailty risk in the short-term for care of people with HIV.
AIDS 2023 May 1; 37(6):967-75. doi: 10.1097/qad.0000000000003501..
Keywords: Human Immunodeficiency Virus (HIV), Risk
Schnall R, Sanabria G, Jia R, Sanabria G, Jia H
Efficacy of an mHealth self-management intervention for persons living with HIV: the WiseApp randomized clinical trial.
This study’s objective was to determine the efficacy of WiseApp, a user-centered design mHealth intervention to improve antiretroviral therapy (ART) adherence and viral suppression in persons living with HIV (PLWH). This randomized case-control trial had two study arms: a randomized controlled efficacy trial arm (n = 99) and an attention control intervention arm (n = 101) among PLWH living in New York City. The authors found a significant improvement in ART adherence in the intervention arm compared to the attention control arm from day 1 (69.7% vs 48.3%) to day 59 (51.2% vs 37.2%) of the study period. From day 60 to 120, the intervention had higher but not statistically significant adherence rates. Secondary analyses showed no difference in change from baseline to 3 or 6 months between the 2 study arms.
AHRQ-funded; HS025071.
Citation: Schnall R, Sanabria G, Jia R, Sanabria G, Jia H .
Efficacy of an mHealth self-management intervention for persons living with HIV: the WiseApp randomized clinical trial.
J Am Med Inform Assoc 2023 Feb 16; 30(3):418-26. doi: 10.1093/jamia/ocac233..
Keywords: Telehealth, Patient Self-Management, Human Immunodeficiency Virus (HIV), Chronic Conditions, Health Information Technology (HIT)
Sun CJ, Shato T, Steinbaugh A
Virtual voices: examining social support exchanged through participant-generated and unmoderated content in a mobile intervention to improve HIV antiretroviral therapy adherence among GBMSM.
The goal of this study was to investigate how social support was provided and sought by gay, bisexual, and other men who have sex with men (GBMSM) within a technology-based antiretroviral therapy (ART) adherence intervention. Participants used the messaging feature in to discuss and exchange support around HIV treatment and care. The most salient HIV treatment and care issues were lab results, upcoming tests, ART adherence and side effects, regimen changes, and relationships with healthcare providers. The authors concluded that this analysis provided an opportunity to understand how participants informally interact with one another, how they seek and provide social support online, and their relevant personal issues.
AHRQ-funded; HS022981.
Citation: Sun CJ, Shato T, Steinbaugh A .
Virtual voices: examining social support exchanged through participant-generated and unmoderated content in a mobile intervention to improve HIV antiretroviral therapy adherence among GBMSM.
AIDS Care 2023 Jan;35(1):7-15. doi: 10.1080/09540121.2022.2038364.
Keywords: Patient Adherence/Compliance, Human Immunodeficiency Virus (HIV), Telehealth, Health Information Technology (HIT), Medication, Vulnerable Populations
Coburn SB, Lang R, Zhang J
Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation.
The purpose of this study was to describe trends in statin eligibility and subsequent statin initiation among people with HIV (PWH) from and identify the predictors of statin initiation. The researchers collected data from 12 United States cohorts between 2001 and 2017. The study found that among 16,409 PWH, 45% met statin eligibility criteria per guidelines for the time period from 2001 to 2017. Statin eligibility ranged from 22% to 25% from 2001 to 2013, and initiation increased from 13% to 45%. In 2014, 51% were statin-eligible, among whom 25% initiated statins, which increased to 32% by 2017. The researchers concluded that there is a substantial statin treatment gap, expanded by the 2013 ACC/AHA guidelines.
AHRQ-funded; 90047713.
Citation: Coburn SB, Lang R, Zhang J .
Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation.
J Acquir Immune Defic Syndr 2022 Dec 15;91(5):469-78. doi: 10.1097/qai.0000000000003083..
Keywords: Medication, Human Immunodeficiency Virus (HIV), Access to Care, Practice Patterns, Cardiovascular Conditions
Rich KM, Zubiago J, Murphy M
The association of gender with receptive and distributive needle sharing among individuals who inject drugs.
The authors sought to assess the relationship between gender and needle sharing with injection drug use. Using data from the 2010-2019 National Survey on Drug Use and Health (NSDUH) datasets, they found that women were more likely in comparison with men to share needles both through receptive and distributive means. They concluded that expansion of interventions, including syringe service programs, to increase access to sterile injection equipment, is of great importance.
AHRQ-funded; HS026008.
Citation: Rich KM, Zubiago J, Murphy M .
The association of gender with receptive and distributive needle sharing among individuals who inject drugs.
Harm Reduct J 2022 Sep 30;19(1):108. doi: 10.1186/s12954-022-00689-3..
Keywords: Human Immunodeficiency Virus (HIV), Substance Abuse, Behavioral Health, Sex Factors
Edwards JK, Cole SR, Breger TL
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
This study examined 5-year mortality for adults entering human immunodeficiency virus (HIV) care under universal early treatment compared with the general US population. A total of 82,766 adults entering HIV treatment at North American AIDS Cohort Collaboration clinical sites in the United States were used to compute mortality over 5 years. The authors used NCHS data to construct a cohort representing a subset of the US population matched to study participants on key characteristics. For the study period of 1999 to 2017, the 5-year mortality among adults with HIV was 7.9% higher than expected based on the US general population. Under universal early treatment, the elevation in mortality for people with HIV would have been 7.2%. During the most recent calendar period examined (2011-2017) the elevation in mortality for people with HIV was 2.6% under observed treatment patterns and 2.1% under universal early treatment.
AHRQ-funded; 90047713.
Citation: Edwards JK, Cole SR, Breger TL .
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
Clin Infect Dis 2022 Sep 14;75(5):867-74. doi: 10.1093/cid/ciab1030..
Keywords: Human Immunodeficiency Virus (HIV), Mortality, Outcomes
McGinnis KA, Justice AC, Moore RD
Discrimination and calibration of the veterans aging cohort study index 2.0 for predicting mortality among people with human immunodeficiency virus in North America.
Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), the authors translated Veterans Aging Cohort Study (VACS) Index 2.0 scores into validated probability estimates of mortality among people with HIV (PWH). They found that predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups. Based on this validation, they concluded that VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.
AHRQ-funded; 90047713.
Citation: McGinnis KA, Justice AC, Moore RD .
Discrimination and calibration of the veterans aging cohort study index 2.0 for predicting mortality among people with human immunodeficiency virus in North America.
Clin Infect Dis 2022 Aug 25;75(2):297-304. doi: 10.1093/cid/ciab883..
Keywords: Human Immunodeficiency Virus (HIV), Chronic Conditions
Korthuis PT, Cook RR, Lum PJ
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Opioid Use Disorder (OUD) treatment medications can improve outcomes for human immunodeficiency virus (HIV) and also reduce opioid use. The purpose of the study was to determine if outpatient naltrexone treatment could also reduce opioid use and improve outcomes for HIV. The researchers reported that enrollment was stopped early because of slower than expected recruitment, resulting in 114 final participants with untreated OUD and HIV, with 62% positive for fentanyl, 60% positive for cocaine, and 47% positive for other opioids at the baseline. The intervention compared treatment as usual (TAU) of methadone or buprenorphine with extended-release naltrexone (XR-NTX) on group differences in viral suppression at 24 weeks and past 30-day use of opioids at 24 weeks. The study reported that at 24 weeks the outcome of viral suppression was similar for TAU and XR-NTX, and that fewer XR-NTX participants initiated medication than TAU participants. The outcome of previous 30-day use of opioids was similar for TAU as compared to XR-NTX. Of those participants who did initiate medication, those administered XR-NTX experienced less days of opioid use when compared with TAU in the prior 30 days. The researchers reported that the study evidence was not conclusive but did support that XR-NTX is not inferior to TAU for HIV viral suppression, and that study participants who started XR-NTX used less opioids at 24 weeks than participants who were administered TAU.
AHRQ-funded; HS026370.
Citation: Korthuis PT, Cook RR, Lum PJ .
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Addiction 2022 Jul;117(7):1961-71. doi: 10.1111/add.15836..
Keywords: Human Immunodeficiency Virus (HIV), Opioids, Substance Abuse, Behavioral Health, Medication, Treatments, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice
Cedillo G, George MC, Deshpande R
Toward safer opioid prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial.
Healthcare and behavioral health providers are lacking a methodology to implement the 2016 U.S. Centers for Disease Control and Prevention Opioid Prescribing Guideline (CDC Guideline), measure prescriber adherence to it, and systematically test its effect on patient and public health outcomes. The Guideline is currently being reviewed and revised due to concern that it may be harmful to people with chronic pain on long-term opioid therapy (CP-LTOT). The purpose of the study was to develop and test a CDC Guideline implementation strategy termed “TOWER,” focused on an outpatient HIV primary care setting with patients with CP-LTOT. The TOWER strategy included: 1) a patient-facing app for opioid management (OM-App); 2) a template for progress notes (OM-Note) intended to guide the patient’s office visit; and 3) a primary care provider (PCP) training. TOWER was developed in a multi-step, stakeholder-engaged process within a behavioral change framework. The researchers evaluated the TOWER strategy in a randomized-controlled trial of HIV-PCPs (N=11) and their patients with HIV and CP-LTOT (N=40). The main outcome was CDC Guideline adherence based on electronic health record (EHR) documentation and measured by the Safer Opioid Prescribing Tool (SOPTET). Qualitative data was also collected, including one-on-one PCP interviews. The study found that the PCPs randomized to utilize the TOWER strategy were 48% more CDC Guideline adherent. Qualitative data reflected high levels of intervention provider confidence in administering the TOWER processes, and that the OM-Note supported provider efforts, but experience with the patient-facing OM-App was mixed. The study concluded that adherence to the 2016 CDC Guidelines is not associated with worsening of outcomes for people with HIV with CP-LTOT, and adherence to the CDC Guidelines can be promoted and measured. The researchers recommend additional research into the scalability of these results and the impact of CDC Guideline adherence on public health.
AHRQ-funded; HS025641.
Citation: Cedillo G, George MC, Deshpande R .
Toward safer opioid prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial.
Addict Sci Clin Pract 2022 May 16;17(1):28. doi: 10.1186/s13722-022-00311-8..
Keywords: Opioids, Medication, Human Immunodeficiency Virus (HIV), Guidelines, Evidence-Based Practice
Kim HN, Nance RM, Lo Re V
Development and validation of a model for prediction of end-stage liver disease in people with HIV.
The authors developed and validated a risk-prediction model for end-stage liver disease (ESLD) among people with HIV (PWH). They developed and validated a risk prediction model for ESLD among PWH who received care in 12 cohorts of the North American AIDS Cohort Collaboration on Research and Design and found that their model of readily accessible clinical parameters predicted ESLD in a large diverse population of PWH.
AHRQ-funded; 90047713.
Citation: Kim HN, Nance RM, Lo Re V .
Development and validation of a model for prediction of end-stage liver disease in people with HIV.
J Acquir Immune Defic Syndr 2022 Apr;89(4):396-404. doi: 10.1097/qai.0000000000002886..
Keywords: Chronic Conditions, Human Immunodeficiency Virus (HIV), Risk
Koh MJ, Merrill MH, Koh MJ
Comparative outcomes for mature T and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Citation: Koh MJ, Merrill MH, Koh MJ .
Comparative outcomes for mature T and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Blood Adv 2022 Mar 8;6(5):1420-31. doi: 10.1182/bloodadvances.2021006208.
AHRQ-funded; 90051652..
AHRQ-funded; 90051652..
Keywords: Human Immunodeficiency Virus (HIV), Comparative Effectiveness, Outcomes, Evidence-Based Practice
Van Gerwen OT, Talluri R, Camino AF
Human immunodeficiency virus/sexually transmitted infection testing preferences for young Black men who have sex with men in the Southeastern United States: implications for a post-COVID-19 era.
Study researchers used a discrete choice experiment to assess the preferences of Young Black Men Who Have Sex with Men (YBMSM) in the Southeastern U.S. regarding their preferences for human immunodeficiency virus (HIV)/ sexually transmitted infection (STI) testing locations, staffing, cost, and hours of operation. Between June 2018 and December 2019, 213 YBMSM between the ages of 16-35 years, located in Birmingham, Alabama and Jackson, Mississippi completed online surveys evaluating their preferences. Traditional, stationary testing locations were preferred by both groups over mobile testing vans. The most significant difference in preference was for local health departments in Alabama, and STI testing-only clinics in Mississippi. Both groups preferred clinician-performed testing over technician-performed testing or self-testing, with additional preferences for free testing and phone results notification (versus text). The most preferred combination among all participants was the $5 clinician-performed testing at the health department. The study concluded that YBMSM in the Southeastern United States prefer traditional testing locations staffed by experienced personnel. The study researchers advise that more research is needed to inform the best ways to approach HIV/STI testing services for YBMSM, especially in the post-COVID-19 era when delivery models are shifting toward health-focused strategies which are home-based and remote.
AHRQ-funded; HS013852.
Citation: Van Gerwen OT, Talluri R, Camino AF .
Human immunodeficiency virus/sexually transmitted infection testing preferences for young Black men who have sex with men in the Southeastern United States: implications for a post-COVID-19 era.
Sex Transm Dis 2022 Mar;49(3):208-15. doi: 10.1097/olq.0000000000001559..
Keywords: COVID-19, Human Immunodeficiency Virus (HIV), Infectious Diseases, Racial and Ethnic Minorities, Men's Health
Wyse JJ, McGinnis KA, Edelman EJ
Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV.
Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). The investigators concluded that history of homelessness was associated with a lower likelihood of retention. Predictors of retention were largely distinct between patients with HIV and patients without HIV. Findings highlighted the need for clinical, systems, and research initiatives to better understand and improve OAT retention.
AHRQ-funded; HS026370.
Citation: Wyse JJ, McGinnis KA, Edelman EJ .
Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV.
AIDS Behav 2022 Mar;26(3):975-85. doi: 10.1007/s10461-021-03452-0..
Keywords: Opioids, Substance Abuse, Behavioral Health, Human Immunodeficiency Virus (HIV)
Higashi RT, Rodriguez SA, Betts AC
Anal cancer screening among women with HIV: provider experiences and system-level challenges.
This article described current practices and barriers met in conducting anal cancer screenings for women living with HIV (WLWH) in an urban integrated safety-net system and in a non-profit community-based HIV clinic. Semi-structured interviews with clinical and administrative stakeholders were conducted to assess their screening for anal cancer experiences, knowledge, clinic practices and procedures. Barriers included limited knowledge of guidelines by providers and system-level issues such as lack of coordination between clinics and limitations on available resources. The authors concluded that screenings and follow-up require organization and coordination between multiple care teams, as well as improved clinical information systems to facilitate communication and infrastructure for managing abnormal results.
AHRQ-funded; HS022418.
Citation: Higashi RT, Rodriguez SA, Betts AC .
Anal cancer screening among women with HIV: provider experiences and system-level challenges.
AIDS Care 2022 Feb; 34(2):220-26. doi: 10.1080/09540121.2021.1883512..
Keywords: Cancer, Human Immunodeficiency Virus (HIV), Women, Screening
Van Gerwen OT, Austin EL, Camino AF
"It's behaviors, not identity": attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States.
Investigators aimed to explore beliefs associated with HIV Pre-Exposure Prophylaxis (PrEP) among transgender women (TGW) in the Southeastern U.S., framed by the Health Belief Model. They identified several themes: frustration with conflation of transgender identity and HIV risk, inappropriate transgender representation in PrEP advertising, concerns for interactions between PrEP and hormone therapy, perception that PrEP is meant for cisgender men who have sex with men, and limited trans-affirming healthcare. Given the diversity of this population, they recommended nuanced messaging to educate and engage TGW in HIV prevention strategies, including PrEP.
AHRQ-funded; HS013852.
Citation: Van Gerwen OT, Austin EL, Camino AF .
"It's behaviors, not identity": attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States.
PLoS One 2022 Jan 27;17(1):e0262205. doi: 10.1371/journal.pone.0262205..
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Sexual Health
Hobson JM, Gilstrap SR, Owens MA
Intersectional HIV and chronic pain stigma: implications for mood, sleep, and pain severity.
This study discusses chronic pain stigma in persons with HIV (PWH) and the consequences for mental and physical health which can lead to poor chronic pain outcome. This cross-sectional study enrolled 91 PWH and chronic pain patients, with six participants disqualified. Participants provided blood to determine CD 4+ count and viral load. They also completed standardized self-report questionnaires that assessed their experiences of HIV and chronic pain stigma, as well as depressive symptoms, experiences of insomnia, and pain severity. Measures used in the questionnaires included the HIV Stigma Mechanisms Scale, the Internalized Stigma of Chronic Pain scale, the Center for Epidemiologic Studies Depression (CED-S) Scale, the Insomnia Severity Index (ISI), and the Brief Pain Inventory Short-Form (BFI-SF). Participants were also questioned on opioid use. Results showed that for intersectional HIV and chronic pain stigma, 38% of participants were categorized as “high”, 28% were categorized as “moderate”, and 34% were categorized as “low”.
AHRQ-funded; HS013852.
Citation: Hobson JM, Gilstrap SR, Owens MA .
Intersectional HIV and chronic pain stigma: implications for mood, sleep, and pain severity.
J Int Assoc Provid AIDS Care 2022 Jan-Dec;21:23259582221077941. doi: 10.1177/23259582221077941..
Keywords: Human Immunodeficiency Virus (HIV), Pain, Chronic Conditions, Social Stigma, Depression
Cook RR, Torralva R, King C
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
This study examined the associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder (OUD) among people living with uncontrolled HIV disease. Data from a multisite clinical trial was used to compare extended-release naltrexone (XR-NTX) with treatment as usual (TAU: buprenorphine or methadone) to achieve HIV viral suppression among people with OUD and uncontrolled HIV disease. Exposure to fentanyl use was measured by urine drug screening. The cohort was 11 participants had an average age of 47 years, were 62% male, 57% Black and 13% Hispanic. Baseline fentanyl use was 64% for participants. Participants with baseline fentanyl use were 11 times less likely to initiative XR-NTX than those negative for fentanyl, but there was no evidence that fentanyl use impacted the likelihood of TAU initiation.
AHRQ-funded; HS026370.
Citation: Cook RR, Torralva R, King C .
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
Drug Alcohol Depend 2021 Nov 1;228:109077. doi: 10.1016/j.drugalcdep.2021.109077..
Keywords: Opioids, Medication, Substance Abuse, Behavioral Health, Human Immunodeficiency Virus (HIV), Chronic Conditions